A hybrid geometric phase II/III clinical trial design based on treatment failure time and toxicity

• Published in: Journal of statistical planning and inference Vol. 142; no. 4; pp. 944 - 955
• Main Authors: Thall, Peter F., Nguyen, Hoang Q., Wang, Xuemei, Wolff, Johannes E.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.04.2012
• Subjects: Bayesian design; Clinical trial; Phase II/III design; Treatment selection; Phase II/III design; Clinical trial; Bayesian design; Treatment selection
• ISSN: 0378-3758; 1873-1171
• DOI: 10.1016/j.jspi.2011.10.016

The problem of comparing several experimental treatments to a standard arises frequently in medical research. Various multi-stage randomized phase II/III designs have been proposed that select one or more promising experimental treatments and compare them to the standard while controlling overall Type I and Type II error rates. This paper addresses phase II/III settings where the joint goals are to increase the average time to treatment failure and control the probability of toxicity while accounting for patient heterogeneity. We are motivated by the desire to construct a feasible design for a trial of four chemotherapy combinations for treating a family of rare pediatric brain tumors. We present a hybrid two-stage design based on two-dimensional treatment effect parameters. A targeted parameter set is constructed from elicited parameter pairs considered to be equally desirable. Bayesian regression models for failure time and the probability of toxicity as functions of treatment and prognostic covariates are used to define two-dimensional covariate-adjusted treatment effect parameter sets. Decisions at each stage of the trial are based on the ratio of posterior probabilities of the alternative and null covariate-adjusted parameter sets. Design parameters are chosen to minimize expected sample size subject to frequentist error constraints. The design is illustrated by application to the brain tumor trial.